DB:O6C

Stock Analysis Report

Executive Summary

MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally.


Snowflake Analysis

Imperfect balance sheet with limited growth.


Similar Companies

Share Price & News

How has MDxHealth's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: O6C's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.8%

O6C

-4.9%

DE Biotechs

-3.0%

DE Market


1 Year Return

-59.0%

O6C

-12.7%

DE Biotechs

-20.6%

DE Market

Return vs Industry: O6C underperformed the German Biotechs industry which returned -10.6% over the past year.

Return vs Market: O6C underperformed the German Market which returned -20.4% over the past year.


Shareholder returns

O6CIndustryMarket
7 Day-5.8%-4.9%-3.0%
30 Day-29.0%-10.3%-19.1%
90 Day-41.4%-22.8%-26.2%
1 Year-59.0%-59.0%-12.5%-12.7%-18.3%-20.6%
3 Yearn/a15.6%14.3%-18.8%-25.6%
5 Yearn/a-8.6%-11.0%-19.9%-30.7%

Price Volatility Vs. Market

How volatile is MDxHealth's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MDxHealth undervalued compared to its fair value and its price relative to the market?

2.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate O6C's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate O6C's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: O6C is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: O6C is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate O6C's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: O6C is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is MDxHealth forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

50.4%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if O6C's forecast earnings growth is above the savings rate (-0.4%).

Earnings vs Market: Insufficient data to determine if O6C's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: O6C's revenue (50.4% per year) is forecast to grow faster than the German market (4% per year).

High Growth Revenue: O6C's revenue (50.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if O6C's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MDxHealth performed over the past 5 years?

-26.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: O6C is currently unprofitable.

Growing Profit Margin: O6C is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: O6C is unprofitable, and losses have increased over the past 5 years at a rate of -26.2% per year.

Accelerating Growth: Unable to compare O6C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: O6C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: O6C has a negative Return on Equity (-218.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is MDxHealth's financial position?


Financial Position Analysis

Short Term Liabilities: O6C's short term assets ($30.9M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: O6C's short term assets ($30.9M) exceed its long term liabilities ($10.5M).


Debt to Equity History and Analysis

Debt Level: O6C's debt to equity ratio (48.8%) is considered high.

Reducing Debt: O6C's debt to equity ratio has increased from 0.01% to 48.8% over the past 5 years.


Balance Sheet

Inventory Level: O6C has a low level of unsold assets or inventory.

Debt Coverage by Assets: O6C's debt is covered by short term assets (assets are 3.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: O6C has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: O6C has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8% each year


Next Steps

Dividend

What is MDxHealth's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate O6C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate O6C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if O6C's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if O6C's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of O6C's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Mike McGarrity (56yo)

1.17s

Tenure

Mr. Michael K. McGarrity, also known as Mike, has been the Chief Executive Officer and Director at MDxHealth SA since February 19, 2019. Mr. McGarrity has more than 25 years of experience in the healthcare ...


Leadership Team

NamePositionTenureCompensationOwnership
Michael McGarrity
CEO & Director1.17yrsno datano data
Ron Kalfus
Chief Financial Officer1.25yrsno datano data
Miriam Reyes
Executive Vice President of Operations1.25yrsno datano data
Wim Van Criekinge
Chief Scientific Officerno datano datano data
Joseph Sollee
Chief Compliance Officerno datano datano data
Jean-Marc Roelandt
CFO & Executive VP (Leave of Absence)3.25yrsno datano data
Paul Marr
Executive Vice President of Sales for North America2.67yrsno datano data
John Bellano
Chief Commercial Officer1.25yrsno datano data

1.3yrs

Average Tenure

50yo

Average Age

Experienced Management: O6C's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael McGarrity
CEO & Director1.17yrsno datano data
Rudi Mariën
Non-Executive Director8.83yrsno datano data
Hilde Windels
Independent Non-Executive Director2.5yrsUS$27.00kno data
Jan Pensaert
Non-Executive Director5.92yrsno datano data
Jan Groen
Advisor to the Board1.17yrsUS$480.37kno data
James Herman
Member of Scientific Advisory Boardno datano datano data
Gerrit Meijer
Member of Scientific Advisory Boardno datano datano data
Jonathan Epstein
Member of Scientific Advisory Board9.08yrsno datano data
Eric Wallen
Member of Scientific Advisory Board9.08yrsno datano data
Koen Hoffman
Independent Non-Executive Chairman2.25yrsUS$20.00kno data

4.2yrs

Average Tenure

55yo

Average Age

Experienced Board: O6C's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.4%.


Top Shareholders

Company Information

MDxHealth SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MDxHealth SA
  • Ticker: O6C
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €43.234m
  • Shares outstanding: 70.53m
  • Website: https://www.mdxhealth.com

Number of Employees


Location

  • MDxHealth SA
  • CAP Business Center
  • Rue d’Abhooz, 31
  • Herstal
  • Liège
  • 4040
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDXHENXTBR (Euronext Brussels)YesOrdinary SharesBEEURJun 2006
0O8GLSE (London Stock Exchange)YesOrdinary SharesGBEURJun 2006
MXDH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2006
MDXHBBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 2006
O6CDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2006

Biography

MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company’s product pipeline includes tests for prostate, bladder, kidney, cervical, and brain cancers. Its products include ConfirmMDx, a tissue-based epigenetic test for prostate cancer; SelectMDx, a urine-based mRNA test for prostate cancer; and AssureMDx bladder cancer detection test for patients with unresolved hematuria. The company’s preclinical development products comprise InformMDx, a tissue-based gene expression panel for prostate cancer; SelectMDx assay to a point of care testing platform; and MonitorMDx, a blood-based test for prostate cancer. It has collaboration agreement with 3D Signatures Inc. to evaluate prognostic test candidate for prostate cancer; and Ghent University to develop cancer biomarker visualization technology. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/02 23:22
End of Day Share Price2020/04/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.